Skip to Content

Haemophilus b conjugate (prp-t) vaccine Disease Interactions

There are 2 disease interactions with haemophilus b conjugate (prp-t) vaccine:

Major

Vaccines (applies to haemophilus b conjugate (prp-t) vaccine) IM injection

Major Potential Hazard, Moderate plausibility. Applicable conditions: Thrombocytopenia, Thrombocytopathy, Coagulation Defect

In patients with thrombocytopenia or coagulation disorders, intramuscular injections may produce bleeding and hematomas. Patients with a platelet count less than 50,000/mm3 are at an increased risk. Caution is advised if the vaccine (e.g., plague vaccine, hepatitis A and B vaccines, and aluminum-adsorbed DTaP, DTP, DT, or Td) must be administered intramuscularly. The risk of bleeding may be minimized by vaccination immediately after the administration of replacement factor, use of a 23-gauge (or smaller) needle, and immediate application of direct pressure to the vaccination site for at least 2 minutes.

References

  1. "Product Information. Cholera vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases. 24th" Grove Village, IL: American Academy of Pediatrics (1997):
  3. "Product Information. Engerix-B (hepatitis B vaccine)." SmithKline Beecham, Philadelphia, PA.
  4. "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.
  5. "Product Information. Plague Vaccine (plague vaccine)." Greer Laboratories Inc, Lenoir, NC.
View all 5 references
Moderate

Vaccines (live attenuated/toxoid) (applies to haemophilus b conjugate (prp-t) vaccine) immunocompromised

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency

The expected antibody responses may not be obtained when live attenuated vaccines and/or toxoids are administered to immunosuppressed persons, including those receiving immunosuppressive therapy. Caution and close monitoring is advised.

Haemophilus b conjugate (prp-t) vaccine drug interactions

There are 224 drug interactions with haemophilus b conjugate (prp-t) vaccine

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.